Journal
Blood Cancer Journal
Publication Date
2021
Volume
11
Issue
5
First Page
89
Document Type
Open Access Publication
DOI
10.1038/s41408-021-00478-4
Rights and Permissions
Mikhael, J., Belhadj-Merzoug, K., Hulin, C. et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 11, 89 (2021). https://doi.org/10.1038/s41408-021-00478-4 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Mikhael, Joseph; Vij, Ravi; and al., et, "A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab." Blood Cancer Journal. 11, 5. 89 (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10536
